Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review

Tomoki Makino1 | Makoto Yamasaki1 | Koji Tanaka1 | Yasuhiro Miyazaki1 | Tsuyoshi Takahashi1 | Yukinori Kurokawa1 | Masaaki Motoori2 | Yutaka Kimura3 | Kiyokazu Nakajima1 | Masaki Mori1 | Yuichiro Doki1

1Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan
2Department of Surgery, Osaka General Medical Center, Osaka, Japan
3Department of Surgery, Faculty of Medicine, Kindai University, Osaka, Japan

Correspondence
Tomoki Makino, Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Email: tmakino@gesurg.med.osaka-u.ac.jp

Abstract

Background: Survival of patients with cT4 esophageal cancer is dismal. Although the optimal treatment strategy remains to be established, two treatment options are available for cT4 esophageal cancers: definitive chemoradiation (dCRT) and induction treatment followed by conversion surgery (CS). However, little is known concerning the differences in clinical outcome between patients with T4 esophageal tumors treated with dCRT and those eventually treated with CS.

Methods: A systematic search of the scientific literature on PubMed/MEDLINE was carried out using the keywords “T4 esophageal cancer,” “invading (involving) adjacent organ,” “definitive chemoradiation,” “induction therapy,” “salvage surgery,” and “conversion surgery,” obtaining 28 reports published up to July 2018.

Results/Conclusion: We found that CS was superior to dCRT with respect to local disease control and short-term survival; however, CS was associated with relatively higher perioperative mortality and morbidity. Alternatively, although dCRT might often cause fistula formation, a clinical complete response to dCRT is likely to lead to a better prognosis. Recent advances in chemotherapeutic agents have led to triple induction chemotherapy, with docetaxel, cisplatin, and 5-fluorouracil (DCF), which has shown promise as an initial induction treatment for cT4 esophageal cancer. Indeed, this regimen could control both local and systemic disease, which enables curative resection without preoperative CRT. Moreover, some appropriate changes in perioperative management and intensive systemic chemotherapy might enhance patient outcome. Randomized controlled trials with a large sample size are needed to establish the standard treatment for cT4 esophageal cancer.

KEYWORDS
conversion surgery, definitive chemoradiation, esophageal cancer, induction chemotherapy, T4
Esophageal cancers tend to invade adjacent organs, including the trachea, bronchus, lung, and aorta, as a result of the lack of serosa in the esophagus and the fact that this conduit is located in a very narrow mediastinal space.\textsuperscript{1,2} Tumors that invade adjacent organs are classified as T4, according to the TNM staging system of the International Union against Cancer (UICC). Despite recent advances in multidisciplinary treatments, the prognosis of patients with T4 esophageal cancer remains unsatisfactory.\textsuperscript{3} Although esophageal cancer is associated with a high incidence of morbidity and mortality, treating with surgery alone, where neighboring organs are resected together with an esophagectomy, has not improved survival.\textsuperscript{4-7} Similarly, definitive chemoradiation (dCRT), a maximum-dose irradiation together with chemotherapy used as a curative treatment which many investigators consider the most suitable treatment for T4 esophageal cancer, has not dramatically contributed to improving patient survival.\textsuperscript{8} As a result of a paucity of evidence, a treatment strategy for T4 esophageal cancer has not been established to date. According to the Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus, 2017, the current standard chemotherapeutic regimen for treating esophageal cancer is 5-fluorouracil (5-FU) combined with cisplatin (CF) because of their synergistic radiosensitizing effects.\textsuperscript{9} Previous studies have reported that concurrent CRT with a CF regimen was effective for treating advanced esophageal cancers, including T4 tumors.\textsuperscript{5,11} Thus, two modalities are currently in use for the treatment of cT4 esophageal tumors: dCRT\textsuperscript{14-19} and induction chemotherapy or CRT, followed by conversion surgery (CS).\textsuperscript{12,13,20-27} Theoretically, when surgery completely removes the tumor, survival should be prolonged, regardless of the T stage. Thus, effective induction treatments must be established for T4 tumors to achieve curative resections, even for initially unresectable tumors.\textsuperscript{30} However, to our knowledge, there is little or no information on the differences in clinical outcome between patients with T4 esophageal tumors treated with dCRT and those eventually treated with CS.

Recently, new triplet chemotherapy regimens have been reported to yield high response rates for esophageal squamous cell carcinoma (ESCC).\textsuperscript{31,32} In particular, docetaxel plus CF (DCF) was shown to be more effective for treating ESCC than the standard treatment of CF or CF plus adriamycin (ACF).\textsuperscript{31} Some studies showed promising results when induction chemotherapy with the DCF regimen was applied before carrying out CS for cT4 ESCC.\textsuperscript{20,24,30} In the present review, we focus on these treatments and the outcomes in patients with T4 esophageal cancer, and we discuss future perspectives regarding these modalities.

2 | MATERIALS AND METHODS

We conducted a systematic search of the scientific literature on PubMed/MEDLINE to obtain all relevant articles involving T4 esophageal cancers published up to July 2018. In the searches, we excluded all non-English articles. To avoid duplications of data, articles from the same unit or hospital were included only once, when data were being updated in a later publication. The search terms were “T4 esophageal cancer,” “invading (involving) adjacent organ,” “definitive chemoradiation,” “induction therapy,” “salvage surgery,” and “conversion surgery.” All available major publications (primarily from high-volume surgical centers) were considered. Articles were selected when the abstract indicated that data were collected on patients with T4 esophageal cancer included in randomized controlled trials (RCT), other cohorts, or comparative studies. We also reviewed the reference lists of these articles to find additional candidate studies. For the present study, data were taken from the published reports; authors were not contacted to obtain additional information. Therefore, articles that lacked necessary data, including survival information according to each treatment group, were excluded from this systematic review. Reports with fewer than 10 cases were also excluded from this study.

3 | RESULTS

3.1 | Studies included in the present review

A flow chart of the article selection process is shown in Figure S1. A total of 28 articles regarding dCRT or/and induction treatment, followed by CS for cT4 esophageal cancer were finally selected (Table 1).

3.2 | Definitive chemoradiation

3.2.1 | Chemoradiation regimen

As summarized in Tables 1 and 2, a total of 16 studies\textsuperscript{12-19,33-40} examined the outcome of patients with T4 esophageal cancer after dCRT. Two major clinical studies on dCRT for esophageal cancer conducted in Japan, termed JCOG9516\textsuperscript{18} and JCOG0303,\textsuperscript{36} were carried out primarily by the Japanese Clinical Oncology Group. Of the 16 studies, 13\textsuperscript{12,13,15-19,33,34,36,38-40} used CF, and three recent studies\textsuperscript{34,35,37} reported the concurrent use of triplet chemotherapy (DCF). Font et al\textsuperscript{14} used a weekly docetaxel regimen (20 mg/m\textsuperscript{2}). Concurrent radiotherapy was applied in all studies, with a total external radiation dose of 50–66 Gy.

3.2.2 | Adverse effects, morbidity, and mortality

The most common early adverse effects associated with dCRT were hematotoxicities, including leukocytopenia, neutropenia, and thrombocytopenia (Table 2). In contrast, esophagitis, anorexia, oral mucositis, and esophageal dysphagia were common non-hematotoxicities (Table 2). Fistula formation, including esophagotracheal (bronchial or pulmonary) and esophagoceliac fistulas, was observed in 9%-22%\textsuperscript{16,18,19,33-37,39,40} of patients with cT4 esophageal cancer during or after dCRT. In the JCOG0303 trial,\textsuperscript{36} which included patients with cT4 and/or
unresectable regional lymph node metastasis, grades 3-4 fistula formation occurred in 32 of 140 patients (23%) during or after dCRT. Intercurrent deaths occurred (massive bleeding from an esophageal-aortic fistula and pneumonia due to an esophageal-pulmonary fistula) in two patients that were treated with a standard CF dose and 60 Gy radiation. One concurrent death was caused by massive bleeding as a result of an esophageal-tracheal fistula. Chiarion-Sileni et al\(^\text{12}\) reported that tracheo-esophageal fistulas developed in 24% of patients with unresectable locally advanced ESCC treated with DCF, followed by carboplatin and radiotherapy. Nishimura et al\(^\text{19}\) studied 28 patients with T4 ESCC that underwent dCRT (60 Gy/CF). They reported worsening or development of esophageal fistulas in five (18%) patients and two (7%) treatment-related deaths.

Incidence of late toxicities as a result of dCRT was 0%-22%, although only five studies reported relevant data\(^\text{12,16,34,36,37}\). In addition to fistula formation, the JCGO3003 study\(^\text{36}\) reported other common late toxicities, including dyspnea, dysphagia/esophagitis/odynophagia, and pneumonia. Seto et al\(^\text{12}\) followed nine patients that survived more than 1 year from the start of dCRT; they reported no late toxicity-related deaths, but they observed 2 pericardial effusion and radiation pneumonitis in four and two patients, respectively. An analysis of data from 14 studies\(^\text{12,14–16,18,19,33–40}\) with relevant data indicated that the dCRT-related mortality rate ranged from 0% to 10%. The main causes of dCRT-related deaths were esophageal fistula with massive bleeding\(^\text{16,18,19}\) and pneumonia\(^\text{14}\).

### 3.2.3 | Response to dCRT and patient survival

We found that patients with T4 tumors experienced a clinical complete response (cCR) of 0%-39% and an overall response rate (both complete and partial responses) of 57%-88% (Table 2)\(^\text{16–19,33–35,40}\). In contrast, the 1-, 3-, and 5-year overall survival (OS) rates of patients with T4 esophageal cancer that received dCRT were 26%-79%, 0%-44%, and 0%-14%, respectively\(^\text{12–19,33–38,40}\). Seto et al\(^\text{12}\) examined prognosis according to the response to CRT; they reported that the 1-, 3-, and 5-year survival rates of patients that experienced cCR and non-cCR were 83%, 33%, 33%, and 23%, 0%, respectively. Itoh et al\(^\text{17}\) also reported that patients that achieved cCR had a significantly better prognosis than those with non-cCR (1-, 3-, 5-year OS rates: 83%, 25%, 25% vs 26%, 7%, 0%; \(P = 0.0317\)). In a phase I/II study of DCF with concurrent radiation (60 Gy), Miyazaki et al\(^\text{35}\) reported that the CR rate and overall response rate were 48% and 86%, respectively, in patients with cT4 esophageal cancer. Accordingly, the prognosis of patients with T4 esophageal cancer that received dCRT depends on whether cCR can be achieved. However, patients that achieved cCR after dCRT sometimes developed disease recurrence. Therefore, careful follow up is necessary, even after achieving cCR. In addition, for recurrence or persistent disease after cCR, salvage surgery or palliation may be indicated, depending on the clinical situation and the patient’s general condition.

### 3.3 | Conversion surgery following induction treatments

#### 3.3.1 | Regimen

As shown in Tables 1 and 3, 14 studies\(^\text{12,13,20–29,41,42}\) have analyzed the outcome of patients with T4 esophageal cancer that underwent CS following induction treatments of CRT (often given with a radiation dose of 40-50.4 Gy with the intention to explore the possibility of carrying out curative surgery later on) or chemotherapy. In all studies, the combination of CF with concurrent 36-60 Gy irradiation was the most common regimen used as primary treatment\(^\text{12,13,20–22,25–29,41,42}\). All CRT in these series were carried out as a "planned" treatment before surgical resection; therefore, after induction treatment, the indication for CS was the relief of T4 invasion. The interval between the completion of CRT and CS was 3-8 weeks in all studies with available related data (Table 3)\(^\text{13,20–22,24,26,27,29,42}\). Alternatively, some more recent studies applied triplet chemotherapy regimens, including DCF, ACF\(^\text{20,24}\) and the combination of 5-FU, adriamycin, and nedaplatin (FAN)\(^\text{22}\).

#### 3.3.2 | Toxicity and mortality as a result of induction CRT or chemotherapy

Yano et al\(^\text{29}\) reported that the most common major toxicities (grade 3-4) caused by CRT (40 Gy/CF) were leukocytopenia (49%), followed by gastrointestinal toxicities (47%). In that study, one patient (2%) died of a treatment-related cause (pancytopenia). Ikeda et al\(^\text{28}\) reported that CRT (60 Gy/CF) caused grade 3 toxicity, particularly hematological reactions, in 13.5% (5/37) of patients (14% anemia and 14% leukocytopenia). They also observed one toxicity-related death (sepsis). In addition, two patients developed esophagobronchial fistulas, two developed esophagogastrovascular fistulas, and one developed an esophagomedial fistula. In the phase II study of chemoselection with DCF chemotherapy and subsequent CS (ie, the COSMOS trial)\(^\text{20}\), the major hematological toxicities (grades 3-4) as a result of induction DCF chemotherapy were leukopenia (41.7%) and neutropenia (66.6%). Moreover, despite an antibiotic prophylaxis application, febrile neutropenia occurred in 11 (22.9%) patients. The most common non-hematological adverse events, above grade 3, were anorexia (25.0%), diarrhea (10.4%), and nausea (4.2%). However, no grade 4 non-hematological adverse event or treatment-related death was observed during induction DCF. Two patients developed treatment-related esophageal fistulas. In contrast, in that same trial, CRT was associated with several grade 3 hematological toxicities, including leukopenia (27.8%), neutropenia (5.6%), and anemia (11.1%). Moreover, grade 3 non-hematological toxicities occurred, including esophagitis, dysphasia, anorexia, and nausea (n = 1 each). No esophageal fistula occurred with CRT. Several late complications occurred after CRT, including grade 1-2 pneumonitis, grade 1 lung abscess, grade 3 esophagitis, and grade 3 anorexia. There was one treatment-related death (respiratory bleeding) in a patient that received DCF chemotherapy followed by CRT (60 Gy).
| Authors               | Design | Year | N  | Histology (SCC/AC/Other) | Treatment (N) | Total radiation dose/chemotherapy regimen | 1/3/5-year overall survival rate (%) |
|----------------------|--------|------|----|--------------------------|---------------|------------------------------------------|-------------------------------------|
| Yokota et al<sup>20</sup> (COSMOS) | P2     | 2016 | 48 | 47/0/1                   | CRT = 20      | DCF (n = 18) DCF+ 30-60 Gy/CF (n = 2)    | 100/90/NA                           |
| Ohira et al<sup>21</sup> | Retro  | 2015 | 91 | 91/0/0                   | CRT = 40      | 40-60 Gy/CF or FN                         | NA/NA/51                            |
| Akutsu et al<sup>21</sup> | Retro  | 2014 | 40 | 40/0/0                   | CRT = 28 (early responders) 12 (late responders) | 40 Gy/CF S3 Gy/CF                        | 74/48/26 72/36/37                      |
| Shimoji et al<sup>22</sup> | Cohort | 2013 | 43 | 42/1/0                   | CRT = 30      | 40-66 Gy/FN (n = 17) FAN (n=26)            | 52/35/35                             |
| Pimiento et al<sup>23</sup> | Retro  | 2013 | 45 | 6/36/3                   | CRT = 45      | NA/platinum-based                         | 75/50/35                             |
| Miyata et al<sup>24</sup> | Retro  | 2012 | 169| 169/0/0                  | CRT = 98      | 40-60 Gy/CF (n = 41) FAP or DCF (n = 41) both (n = 16) | NA/48/40                             |
| Miyoshi et al<sup>26</sup> | Retro  | 2009 | 42 | 42/0/0                   | CRT = 42      | 40 Gy/CF or ACF                           | 66/45/38                             |
| Seto et al<sup>12</sup> | Retro  | 2007 | 88 | 88/0/0                   | CRT = 59      | 60 Gy/CF                                 | 68/38/20                             |
| de Manzoni et al<sup>25</sup> | Retro  | 2007 | 51 | 51/0/0                   | CRT = 51      | 50-60 Gy/CF                              | NA/9/6                               |
| Fujita et al<sup>23</sup> | Cohort | 2005 | 53 | 53/0/0                   | CRT = 23      | 60 Gy/CF                                 | 73/28/17                             |
| Noguchi et al<sup>27</sup> | Retro  | 2003 | 41 | 41/0/0                   | CRT = 41      | 40 Gy/CF                                 | 24/5/0                               |
| Ikeda et al<sup>28</sup> | P2     | 2001 | 37 | 37/0/0                   | CRT = 37      | 60 Gy/CF                                 | 45/23/23                             |
| Yano et al<sup>29</sup>  | Retro  | 1999 | 45 | 45/0/0                   | CRT = 45      | 40 Gy/CF                                 | 48/35/25                             |
| Van Raemdonck et al<sup>30</sup> | Retro  | 1997 | 18 | 15/3/0                   | CRT = 18      | 36-50 Gy/CF or MF                         | 62/43/NA                             |
| Satake et al<sup>33</sup> | P1/2   | 2016 | 33<sup>b</sup> | 33/0/0              | CRT = 33      | DCF→60 Gy/CF                             | 79/40/NA                             |
| Jingu et al<sup>34</sup>  | Retro  | 2016 | 70 | 70/0/0                   | CRT = 70      | 50-70 Gy/CF or DCF or FN                  | 33 (2y)/24 (4y)                       |
| Li et al<sup>30</sup>    | Retro  | 2016 | 56 | 56/0/0                   | CRT = 56      | 54-60 Gy/CF or DC or PC                   | 39/21/NA                             |
| Miyazaki et al<sup>25</sup> | P1/2   | 2015 | 37<sup>b</sup> | 36/1/0              | CRT = 37      | 60 Gy/DCF                                | 78/44/NA                             |
| Shinozaki et al<sup>36</sup> (JCOG0303) | rP2    | 2015 | 142<sup>b</sup> | 142/0/0         | CRT = 71     | 60 Gy/low-dose CF                        | 56<sup>b</sup>/26<sup>b</sup>/NA     |
| Higuchi et al<sup>37</sup> (KDOG0501-P2) | P2     | 2014 | 42<sup>b</sup> | 42/0/0          | CRT = 42     | 50.4-61.2 Gy/DCF                        | 66<sup>b</sup>/44<sup>b</sup>/NA     |
| Font et al<sup>14</sup>   | Retro  | 2007 | 19 | NA/NA/NA                | CRT = 19      | 66 Gy/docetaxel                          | 26/0/0                               |
| Ishida et al<sup>38</sup> (JCOG9516) | P2     | 2004 | 60<sup>b</sup> | 60/0/0          | CRT = 60     | 60 Gy/CF                                 | 38<sup>b</sup>/23<sup>b</sup>/NA     |

(Continues)
### TABLE 1 (Continued)

| Authors                | Design | Year | N   | Histology (SCC/AC/Other) | Treatment (N) | Total radiation dose/chemotherapy regimen | 1/3/5-year overall survival rate (%) |
|------------------------|--------|------|-----|--------------------------|---------------|------------------------------------------|--------------------------------------|
| Crosby et al<sup>15</sup> | Retro  | 2004 | 27  | NA/NA/NA/NA              | CRT 27, CS -  | CRT 50 Gy/CF                            | 45/23/NA                             |
| Kaneko et al<sup>16</sup> | Retro  | 2003 | 35  | 35/0/0                   | CRT 35, CS -  | CRT 60 Gy/CF                            | 45/8/NA                              |
| Nishimura et al<sup>17</sup> | P1/2   | 2002 | 28  | 28/0/0                   | CRT 28, CS -  | CRT 60 Gy/CF                            | 30/NA/NA                             |
| Itoh et al<sup>18</sup>  | Pilot  | 1999 | 36  | 36/0/0                   | CRT 36, CS -  | CRT 60 Gy/CF                            | -                                    |
| Ohtsu et al<sup>19</sup> | Pilot  | 1995 | 20  | 20/0/0                   | CRT 20, CS -  | CRT 60 Gy/CF                            | -                                    |

5FU, 5-fluorouracil; AC, adenocarcinoma; CF, 5-fluorouracil and cisplatin; cohort, cohort study; CRT, chemoradiation; CS, conversion surgery; DC, docetaxel and cisplatin; DCF, docetaxel, cisplatin, and 5-fluorouracil; FAN, 5-fluorouracil, adriamycin, and nedaplatin; FN, 5-fluorouracil and nedaplatin; MF, mitomycin C and 5-fluorouracil; NA, data not available; P(1/)2, phase (I/)II study; PC, paclitaxel and carboplatin; pilot, pilot study; retro, retrospective study; SCC, squamous cell carcinoma.

*postoperative dose. <sup>a</sup>T4/M1 lym tumors.
TABLE 2  Summary of outcomes in definitive chemoradiotherapy group

| Authors                     | Year | N   | Grade 3/4 toxicities (%)                                                                 | Fistula formation (%) | Mortality (%) | Response rate (%) | cCR rate (%) | 1/3/5-year overall survival rate (%) | cCR | Non-cCR |
|-----------------------------|------|-----|------------------------------------------------------------------------------------------|-----------------------|---------------|------------------|-------------|--------------------------------------|-----|---------|
| Satake et al33              | 2016 | 33  | 24° (leukocytopenia) 18° (neutropenia) 15° (dysphagia)                                     | NA                    | 6°            | 0°              | 73          | 39°                                  | NA  | NA      |
| Jingu et al34               | 2016 | 70  | 44° (leukocytopenia) 17° (esophagitis)                                                    | 3° (pneumonitis)      | 5°            | 7°              | NA          | NA NA NA NA NA NA NA NA NA NA NA NA |
| Li et al40                  | 2016 | 56  | 25° (leukocytopenia)                                                                  | NA                    | 11            | 9               | 61          | 23                                   | 92/55/NA | NA      |
| Miyazaki et al35            | 2015 | 37a | 92° (leukocytopenia) 76° (neutropenia) 32° (nausea)                                          | NA                    | 5             | 0               | 86          | 48                                   | NA  | NA      |
| Shinoda et al36 (JCOG0303) | 2015 | 71c | 29° (dysphagia/esophagitis) 21° (leukocytopenia) 21° (anorexia) 26° (leukocytopenia) 23° (dysphagia/esophagitis) 20° (anorexia) | 22° (fistula) 18° (dyspnea) 10° (dysphagia) 12° (fistula) 14° (dyspnea) 11° (dysphagia) | 5°            | 2°             | 86°         | 52°                                  | NA  | NA      |
| (KDOG0501-P2)               |      |     |                                                                                         |                       |               |                 |             |                                      |     |         |
| Higuchi et al37             | 2014 | 42c | 71° (leukocytopenia) 57° (neutropenia) 38° (febrile neutropenia)                         | 8° (esophagitis/stenosis/fistula) | 5°            | 2°             | 86°         | 52°                                  | NA  | NA      |
| Seto et al12                | 2007 | 29  | NA                                                                                      | 0                     | NA            | 0               | NA          | 24                                   | 83/33/33 | 23/0/0  |
| Font et al14                | 2007 | 19  | 17h (esophagitis)                                                                         | NA                    | NA            | 6h             | NA          | NA NA NA NA NA NA NA NA NA NA NA |
| Fujita et al13              | 2005 | 23  | 30° (leukocytopenia) 13° (anemia)                                                        | NA                    | NA            | NA             | 57          | 39                                   | NA  | NA      |
| Ishida et al38 (JCOG9516)   | 2004 | 60c | 33° (leukocytopenia) 10° (liver dysfunction)                                              | NA                    | NA            | 3°             | 68°         | 15°                                  | NA  | NA      |
| Crosby et al15              | 2004 | 27  | 12h (oral mucositis) 10° (leukocytopenia)                                               | NA                    | NA            | 0              | NA          | NA NA NA NA NA NA NA NA NA NA NA |
| Kaneko et al16              | 2003 | 35  | 33h (anemia) 30° (leukocytopenia) 25h (esophagitis)                                       | 0                     | 9             | 6              | NA          | 29                                   | NA  | NA      |
| Nishimura et al19           | 2002 | 23  | 50° (leukocytopenia) 32° (dysphagia) 21° (anemia) 11 (thrombocytopenia)                  | NA                    | 18            | 7              | 88          | 32                                   | NA  | NA      |
| Itoh et al17                | 2001 | 35  | NA                                                                                      | NA                    | NA            | NA             | 68          | 17                                   | 83/25/25 | 26/7/0  |

(Continues)
T4 patients that underwent CS were 24%-100%, 5%-50%, and 0%-51%, respectively. Among the five studies\textsuperscript{22,23,26,27,29,42} that classified prognosis according to the pathological response to CRT, 1-, 3-, and 5-year OS rates were 85%-100%, 61%-100%, and 25%-86%, respectively, for grade 3 tumors, and 20-65%, 0-35%, and 0%-30% for grade 0-2 tumors (Table 3).

Miyata \textsuperscript{et al}\textsuperscript{24} analyzed 98 patients that underwent CRT or triplet chemotherapy plus CRT, with or without subsequent CS; they found that patients that underwent CS had significantly more favorable 3- and 5-year OS rates (48% and 40%, respectively) compared to patients that did not receive CS (7% and 4%, respectively). This trend was also identified in patients that showed a good response to induction treatments and those that showed a poor response using separately analyzed survival data (data not shown). Seto \textsuperscript{et al}\textsuperscript{12} reported that the 1- and 3-year OS rates of 59 patients with cT4 ESCC who underwent neoadjuvant CRT plus esophagectomy were 67.8% and 37.9%, respectively. The 1- and 3-year OS rates were 77.8% and 45.1%, respectively, for R0 resections and 38.5% and 0%, respectively, for palliative resections (R1/2). The prognosis of patients that underwent tracheal resections was poor, even after a R0 resection. de Manzoni \textsuperscript{et al}\textsuperscript{25} analyzed the survival of patients with esophageal cancer according to the infiltrated organs detected on pretreatment staging; they reported that curative resections were possible after CRT (50-60 Gy/CF) when tumors invaded the aorta, but no long-term survivors were observed when tumors had invaded other organs. Among patients with invasions of the aorta, airway, and other organs, the 3-year survival times were 31.3, 4.5, and 0 months, respectively\textsuperscript{25}. Furthermore, median survival times were 22.3 and 9 months for patients with R0 and R1/2 resections, respectively (P < 0.001). The recurrence pattern after a CS for cT4 esophageal cancer was only described in one study by Yano \textsuperscript{et al}\textsuperscript{29} They reported that, among 27 patients, 17 (63%) experienced recurrence after a curative resection; among these 17 recurrences, eight were local, six were distant, two were local plus distant, and one displayed an unknown.

### 3.4 | Triplet chemotherapy as an initial induction treatment

The standard regimen for induction treatment in locally advanced T4 esophageal cancer is concurrent CRT with CF. The CF regimen has not changed in decades, but it is possible that a stronger regimen might improve outcomes. In 2007, a novel regimen of DCF achieved a significant antitumor effect and improved the outcome of patients with head and neck cancer.\textsuperscript{44} DCF was also expected to be effective for ESCC because of its histological similarity to head and neck cancer. Indeed, DCF had a strong antitumor effect for ESCC, and it is currently being used as a first-line chemotherapy regimen for ESCC. DCF even achieved local tumor control comparable to that achieved with CRT; thus, several studies\textsuperscripts{30-32} used DCF as an initial induction treatment for T4 ESCC and confirmed its clinical utility. A recent phase II study (COSMOS trial)\textsuperscript{20} investigated the efficacy of induction DCF chemotherapy. That study

| Grade 3/4 toxicities (%) | Authors | Year | N | Acute: (anemia) | Acute: (leukocytopenia) | Acute: (thrombocytopenia) | Acute: (esophagitis) | Late: Fistula formation (%) | Late: Mortality (%) | cCR rate (%) | Non-cCR rate (%) |
|------------------------|---------|------|----|----------------|-------------------------|------------------------|----------------------|-------------------|-----------------|----------------|----------------|
|                        | Ohtsu \textsuperscript{et al}\textsuperscript{18} | 1999 | 36 | 26\textsuperscript{c} | 24\textsuperscript{c} | 17\textsuperscript{c} | 15\textsuperscript{c} | 14 | 7 | 25 | NA |
|                         | Ohtsu \textsuperscript{et al}\textsuperscript{39} | 1995 | 19 | 45\textsuperscript{c} | 20\textsuperscript{c} | NA | NA | 19 | 81 | 30\textsuperscript{c} | NA |

\textsuperscript{c}Data in patients including Chemoradiotherapy (CRT) and CRT plus surgery group; \textsuperscript{b}T3/4 tumors, or \textsuperscript{c}T4a/M1, Iybn tumors; cCR, clinical complete response; CR, complete response; LDCF, low-dose cisplatin and 5-fluorouracil.
| Authors                  | N  | Intervala (weeks) | Combined resection rate (%) | Postoperative complications (%) | Mortality (%) | Resection rateb (%) | Curative resection rateb (%) | Clinical response rate (%) | pCR rate (%) | 1/3/5-year overall survival rate (%) |
|-------------------------|----|------------------|-----------------------------|--------------------------------|---------------|---------------------|-----------------------------|---------------------------|-------------|-----------------------------------|
| Yokota et al20 (COSMOS)| 20 | within 8         | 0                           | 38 (recurrent nerve palsy) 24 (pleural effusion) 14 (lung infection) | 0             | 42                  | 40                          | NA                        | 20          | 20                                |
| Ohira et al31           | 40 | NA               | 0                           | NA                            | NA            | 45                  | 40                          | 67                        | NA          | NA                                |
| Akutsu et al21          | 28 (early responders) 12 (late responders) | 3-4 | NA                         | NA                            | 0             | 8                   | 26                          | NA                        | 100         | 22 NA NA |
| Shimoji et al22         | 43 | 4 (chemo) 6 (CRT) | 0                           | 63                            | 13            | 70                  | 61                          | 54                        | 14          | 14 NA NA |
| Pimiento et al23        | 45 | NA               | 0                           | total 52 22 (respiratory) 17 (DGE) | 4             | NA                  | 96                          | NA                        | 42          | 42 85/61/53 NA |
| Miyata et al24          | 98 | 3-4              | NA                          | NA                            | NA            | 58                  | 47                          | 78                        | 16          | 16 NA NA |
| Miyoshi et al26         | 42 | 4                | NA                          | NA                            | NA            | NA                  | NA                          | NA                        | NA          | NA |
| Seto et al12            | 59 | NA               | 17 (respiratory tract) 10 (lung) 10 (pericardium) | NA                            | 5             | NA                  | NA                          | NA                        | 14          | 7 NA NA |
| de Manzoni et al25      | 51 | NA               | NA                          | NA                            | 10            | 78                  | 39                          | 20                        | 13          | NA NA |
| Fujita et al13          | 30 | 4-6              | 0                           | total 87 50 (recurrent nerve palsy) 35 (respiratory) 23 (tracheal ischemia) 23 (pyothorax) | 7             | 57                  | 34                          | 63                        | 15          | 7 NA NA |
| Noguchi et al27         | 41 | 4-6              | 0                           | total 29 17 (anastomatic leak) | 21            | 59                  | NA                          | 59                        | 17          | 17 100/75/25 20/0/0 |
| Ikeda et al28           | 37 | NA               | 0                           | NA                            | 0             | 35                  | 32                          | 76                        | 8           | 8 NA NA |
| Yano et al29            | 45 | 4                | NA                          | total 62 43 (respiratory) 25 (delirium) 21 (recurrent nerve palsy) | 0             | 62                  | 44                          | 64                        | 29          | 25 86/86/86 65/35/20 |
| Van Raemdonck et al42   | 18 | 4-8              | 0                           | 11 (recurrent nerve palsy) 11 (surgical site infection) 11 (lymphatic fistula) | 0             | 100                 | 83                          | 50                        | 17          | 17 100/100/ NA 53/32/ NA |

Chemo, chemotherapy; CR, complete response; CRT, chemoradiotherapy; DGE, delayed gastric emptying; NA, data not available; pCR, pathological complete response.

*Interval from the completion of chemoradiotherapy to the operation. bCalculated with intention-to-treat analysis.
aimed to test downstaging the tumor and, subsequently, converting to surgery as a multidisciplinary strategy for treating cT4 ESCC. In that trial, the first-line chemotherapy regimen consisted of three courses of DCF. When resectability was achieved after the third course of DCF, CS was carried out. When resectability was not achieved by the middle evaluation of CRT, dCRT was given. That study reported that CS was carried out in 41.7% of patients, and an R0 resection was confirmed in 39.6% of patients. A point estimate of the 1-year survival rate was 67.7%, and the 80% confidence interval had a lower limit of 59.5%. Because this lower limit was higher than the 50% threshold, this first prospective trial showed a statistically positive effect. In addition, the 1-year survival rate in that study was higher than that found in the standard-dose CF-RT arm in the JCOG0303 trial. This finding indicated that DCF chemotherapy was a sufficiently powerful induction treatment for cT4 ESCC.

Miyata et al. investigated the clinical utility of initial induction triplet chemotherapy with either a DCF or an ACF regimen, with or without a second-line induction CRT, for treating cT4 ESCC. In that study, induction DCF chemotherapy reduced esophageal perforations and increased overall resectability in patients with T4 ESCC, which led to a better survival rate than that achieved with CRT alone. Makino et al., from the same institute, carried out a propensity score-matched analysis. They compared 50 patients with cT4 ESCC that underwent an initial DCF induction therapy to another 50 patients that underwent induction radiotherapy concurrent with a CF regimen (CRT); they reported that the initial induction DCF chemotherapy achieved up to 64% of the clinical response rate which was nearly comparable to the 72.0% achieved with induction CRT. Compared to the CRT group, the DCF group had significantly higher overall resectability (78.0% vs 48.0%, \( P = 0.0017 \)) and survival (5-year cancer-specific survival: 42.1% vs 22.2%, \( P = 0.0146 \)). Considering that local recurrence after curative surgery tended to be lower in the DCF group than in the CRT group, DCF chemotherapy appeared to control local disease sufficiently, with or without subsequent CRT. Another potential benefit of giving induction DCF chemotherapy for T4 ESCC is to control micrometastasis; this application was supported by the finding that survival superiority with DCF was observed only for the node-positive (cN1-3) population. Shimoji et al. conducted a prospective study on a cohort that received FAN induction triplet chemotherapy \((n = 17)\) or CRT \((n = 26)\) each treatment followed, when feasible, by esophagectomy. They also reported that satisfactory survival could be achieved when R0 resection was carried out after induction treatment in T4 ESCC; however, a secondary radical esophagectomy was associated with a higher risk of in-hospital mortality.

Satake et al. conducted a multicenter phase I/II study on induction DCF chemotherapy followed by CRT in patients with unresectable, locally advanced ESCC. In that trial, DCF induction chemotherapy showed promising efficacy with a median progression-free survival of 12 months and a 3-year survival rate of 40.4%. However, 39.4% of the 33 patients with ESCC that involved cT4 and/or M1 lymph achieved a CR; this CR rate was less than expected. A post-JCOG0303 trial was recently started to test a trimodality combination therapy with induction DCF compared to dCRT for locally advanced unresectable (cT4) ESCC of the thoracic esophagus (TRIANgLE; JCOG1511). The aim of this new phase III JCOG study is to confirm that DCF chemotherapy followed by radical surgery or dCRT shows superiority in OS over the standard dCRT for patients with cT4 ESCC of the thoracic esophagus. The primary endpoint of the trial is OS. Secondary endpoints include progression-free survival, (complete) response rate, adverse events of DCF or CRT, late-onset adverse events, and perioperative complications. A total of 230 patients will be recruited from 47 Japanese institutions.

4 | SUMMARY AND PERSPECTIVES

A possible algorithm of treatment for cT4 esophageal cancer is summarized in Figure 1. In the case of dCRT, patient prognosis depends on whether or not cCR can be achieved. However, it is often difficult to determine a treatment strategy after achieving cCR with

---

**Figure 1** Possible algorithm of a treatment strategy for cT4 esophageal cancer. Different treatment strategies, including (A) definitive chemoradiation (CRT), potentially followed by salvage surgery, in the absence of a complete response (CR); or (B) induction treatments potentially followed by conversion surgery. BSC, best supportive care; DCF, docetaxel, cisplatin, and 5-fluorouracil.
dCRT. It is also clinically difficult to make a diagnosis of CR based on endoscopic biopsies, which sometimes give false-negative results, or imaging tools, due to CRT-induced inflammation, fibrosis, or edema. In contrast, it remains controversial whether surgery should play a role in a treatment modality carried out after achieving CR with dCRT. Two randomized trials45,46 have compared preoperative dCRT, followed by surgery, versus dCRT alone to assess the role of surgery in T3 and/or T4 diseases. They found that adding surgery to dCRT provided no survival benefit. Furthermore, significantly higher operative mortality rates and major morbidities, including anastomotic leaks and pulmonary complications, were reported in both trials. These findings were presumably due to the adverse effects of CRT, including radiation-induced fibrosis, which affected thoracic tissue and patient performance status. Meanwhile, as patients that achieved cCR after dCRT sometimes developed disease recurrence, careful follow up is necessary even after achieving cCR. In addition, for recurrence or persistent disease (non-CR) after cCR, salvage surgery (optional) or palliation including chemotherapy may be indicated, depending on the clinical situation and the patient’s general condition (Figure 1A). However, when curative resection is considered possible after induction CRT or DCF, CS might be scheduled. When the tumor remains unresectable (persistent T4), chemotherapy or CRT might subsequently be given, depending on the type of initial induction treatment. In cases with persistent T4 tumors after an initial induction with DCF, a second-line induction CRT might be indicated to pursue any chance of carrying out CS as an optional treatment strategy; this latter option is practiced in our institute (Figure 1B).

Older patients are often excluded, or at least underrepresented, in clinical trials. Thus, it is reasonable to question whether the results are generally transferable to the older population. Although it is true that some older patients are not suitable for intensive multimodality treatment, age alone should not be taken as the decisive factor in making treatment decisions in T4 esophageal cancer. In fact, according to a recent analysis by Pultrum et al.,47 older age did not significantly influence the overall outcome or the complication rate in patients treated with extended esophagectomies. However, the presence of comorbidity had a significant impact on survival. Thus, it might be more appropriate to base treatment decisions on comorbidity and/or performance status, rather than chronological age alone.48 Although we proposed a possible treatment algorithm for ct4 esophageal cancer (Figure 1), the tolerance for each treatment should first be evaluated, considering comorbidity, performance status, and general condition, in addition to the patient’s age. Radiation alone or palliation might be indicated for older patients at high risk; alternatively, a potentially curative treatment strategy might be considered for carefully selected older patients without severe comorbidity.

This review has shown that CS appeared to be superior to dCRT for treating T4 esophageal cancer with respect to local control and short-term prognosis despite the relatively high association with perioperative morbidities. However, although the fistula formation rate was relatively high in dCRT, a CR to CRT might lead to a better prognosis. When more powerful chemotherapy, such as a DCF regimen, is tolerable concurrent with definitive radiation, this is the most promising option for treating T4 esophageal cancer. Also, as an initial induction therapy, triplet chemotherapy, including a DCF regimen, can yield both significant local control and systemic control, which enables the application of CS for T4 esophageal cancer, without preoperative radiation. DCF chemotherapy can also be used for chemoselection, followed by CS or dCRT, as a multidisciplinary treatment strategy. In addition, a number of clinical trials are currently testing immune-checkpoint inhibitors with or without chemotherapy or radiation. These treatments might become viable treatment options for T4 esophageal cancer in the near future. Randomized controlled trials that include a large population are needed to define a standard treatment for T4 esophageal cancer.

DISCLOSURE
Authors declare no conflicts of interest for this article.

ORCID
Tomoki Makino http://orcid.org/0000-0001-7918-4217
Yukinori Kurokawa http://orcid.org/0000-0002-2883-0132

REFERENCES
1. Makino T, Doki Y. Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg. 2011;17:221–8.
2. Gamliel Z, Krasna MJ. Multimodality treatment of esophageal cancer. Surg Clin North Am. 2005;85:621–30.
3. Makino T, Yamasaki M, Tanaka K, et al. Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer. Surgery. 2017;162:836–45.
4. Shimada H, Okazumi S, Matsubara H, et al. Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection. World J Surg. 2006;30:1441–9.
5. Shimada H, Kitabayashi H, Nabeya Y, et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003;133:24–31.
6. Ichiyoshi Y, Kawahara H, Taga S, et al. Indications and operative techniques for combined aortoesophageal resection. Jpn J Thorac Cardiovasc Surg. 1999;47:318–24.
7. Shenfine J, McNamee P, Steen N, et al. A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technol Assess. 2005;9:iii, 1–121.
8. Akutsu Y, Matsubara H. Chemoradiotherapy and surgery for T4 esophageal cancer in Japan. Surg Today. 2015;45:1360–5.
9. Ancona E, Ruol A, Castoro C, et al. First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up. Ann Surg. 1997;226:714–723.
10. John MJ, Flam MS, Mowry PA, et al. Radiotherapy alone and chemoradiation for nonmetastatic esophageal carcinoma. A critical review of chemoradiation. Cancer. 1989;63:2397–403.

11. Tsuchinaka T, Shiozaki H, Yamamoto M, et al. Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma. Am J Surg. 1999;177:503–506; discussion 507.

12. Seto Y, Chin K, Gomi K, et al. Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci. 2007;98:937–42.

13. Fujita H, Sueyoshi S, Tanaka T, et al. Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg. 2005;29:25–30.

14. Font A, Arellano A, Fernandez-Llamazaes J, et al. Weekly docetaxel with concomitant radiotherapy in patients with inoperable esophageal cancer. Clin Transl Oncol. 2007;9:177–82.

15. Crosby TD, Brewster AE, Borley A, et al. Definitive chemoradiation in patients with inoperable esophageal carcinoma. Br J Cancer. 2004;90:70–5.

16. Kaneko K, Ito H, Konishi K, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the esophagus. Br J Cancer. 2003;88:18–24.

17. Itoh Y, Fuwa N, Matsumoto A, et al. Outcomes of radiotherapy for inoperable locally advanced (T4) esophageal cancer: retrospective analysis. Radiat Med. 2001;19:231–5.

18. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.

19. Nishimura Y, Suzuki M, Nakamatsu K, et al. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys. 2002;53:134–9.

20. Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemotherapy with docetaxel plus cisplatin and 5-fluorouracil in unresectable esophageal cancer: results of a prospective cohort study. World J Surg. 2013;37:2180–8.

21. Akutsu Y, Kono T, Usato M, et al. Is the outcome of a salvage surgery for T4 thoracic esophageal squamous cell carcinoma really poor? World J Surg. 2014;38:2891–7.

22. Shimoji H, Karimata H, Yamamoto M, et al. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg. 2013;37:2180–8.

23. Pimienta JM, Weber J, Hoffe SE, et al. Outcomes associated with surgery for T4 esophageal cancer. Ann Surg Oncol. 2013;20:2706–12.

24. Miyata H, Yamasaki M, Kurokawa Y, et al. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol. 2012;106:441–7.

25. de Manzoni G, Pedrazzani C, Pasini F, et al. Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol. 2007;95:261–6.

26. Miyoshi N, Yano M, Takachi K, et al. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. J Surg Oncol. 2009;99:302–6.

27. Noguchi T, Moriyama H, Wada S, et al. Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma. Dis Esophagus. 2003;16:94–8.

28. Ikeda K, Ishida K, Sato N, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001;14:197–201.

29. Yano M, Tsujinaka T, Shiozaki H, et al. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol. 1999;70:25–32.

30. Makino T, Yamashita M, Miyazaki Y, et al. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis. Dis Esophagus 2018;31:https://doi.org/10.1093/dote/dox130.

31. Yamashita M, Yasuda T, Yano M, et al. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol. 2017;28:116–20.

32. Shiraiishi O, Yamasaki M, Makino T, et al. Feasibility of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil versus adriamycin, cisplatin, and 5-fluorouracil for resectable advanced esophageal cancer. Oncology. 2017;92:101–8.

33. Satake H, Tahara M, Mochizuki S, et al. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol. 2016;78:91–9.

34. Jingu K, Umezawa R, Matsushita H, et al. Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan. Int J Clin Oncol. 2016;21:276–82.

35. Miyazaki T, Sohda M, Tanaka N, et al. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2015;75:449–55.

36. Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106:407–12.

37. Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG0501-P2). Int J Radiat Oncol Biol Phys. 2014;89:872–9.

38. Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–9.

39. Ohtsu A, Yoshida S, Boku N, et al. Concurrent chemoradiotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol. 1995;25:261–6.

40. Li M, Zhao F, Zhang X, et al. Involved-field irradiation in definitive chemoradiotherapy for T4 squamous cell carcinoma of the esophagus. Curr Oncol. 2016;23:e131–7.

41. Ohira M, Kubo N, Masuda G, et al. Glasgow prognostic score as a prognostic clinical marker in T4 esophageal squamous cell carcinoma. Anticancer Res. 2015;35:4897–901.

42. Van Raemdonck D, Van Cutsen E, Menten J, et al. Induction therapy for clinical T4 oesophageal carcinoma: a plea for continued surgical exploration. Eur J Cardiothorac Surg. 1997;11:828–37.

43. Chiaroni-Sileni V, Corti L, Ruol A, et al. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer. 2007;96:432–8.

44. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–15.

45. Stahl M, Stuschke M, Lehnmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.
46. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160–8.

47. Pultrum BB, Bosch DJ, Nijsten MW, et al. Extended esophagectomy in elderly patients with esophageal cancer: minor effect of age alone in determining the postoperative course and survival. Ann Surg Oncol. 2010;17:1572–80.

48. Walter F, Bockle D, Schmidt-Hegemann NS, et al. Clinical outcome of elderly patients (≥70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis. Radiat Oncol. 2018;13:93.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Makino T, Yamasaki M, Tanaka K, et al. Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review. Ann Gastroenterol Surg. 2019;3:169–180. https://doi.org/10.1002/ags3.12222